Cargando…

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To improve the therapeutic index of Sunitinib, a prodrug strategy was employed to modify Sunitinib. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Qiang, Zhou, Changhua, Chen, Xiao, Dong, Bing, Chen, Siqi, Zhang, Ning, Liu, Yawei, Li, Anrong, Yao, Meicun, Miao, Ji, Li, Qing, Wang, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626378/ https://www.ncbi.nlm.nih.gov/pubmed/26513662 http://dx.doi.org/10.1371/journal.pone.0141395

Ejemplares similares

The compound AST-003 could effectively promote apoptosis of renal cell carcinoma cells in vitro
por: Tang, Xingxing, et al.
Publicado: (2021)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

Effective Antiviral Activity of the Tyrosine Kinase Inhibitor Sunitinib Malate against Zika Virus
por: Lin, Chen-Sheng, et al.
Publicado: (2021)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
por: Brooks, Colin, et al.
Publicado: (2012)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Angular analysis of $ {B}^0\to {D}^{\ast -}{D}_s^{\ast +} $ with $ {D}_s^{\ast +}\to {D}_s^{+}\gamma $ decays
por: Aaij, Roel, et al.
Publicado: (2021)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

Test of HQET with B^\ast, B^\ast \ast and lifetime measurements of B_s mesons and beauty baryons at DELPHI
por: Siccama, I
Publicado: (1995)

Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
por: Knoerzer, D, et al.
Publicado: (2013)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
por: Sbitti, Yassir, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
por: AlAzab, Rami S, et al.
Publicado: (2019)

Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2019)

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo
por: Jensen, Brian C., et al.
Publicado: (2017)

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2022)

First Observation of the B ^\ast Dalitz Decay B ^\ast -> B\ e ^+ e ^-
por: DELPHI Collaboration
Publicado: (2018)

Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum
por: Borde, Kalyani, et al.
Publicado: (2022)

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
por: Hu, Jialiang, et al.
Publicado: (2020)

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation
por: Greenberg, Jacob W., et al.
Publicado: (2022)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

AST Six Pack Premium
por: Basson, Craig Todd
Publicado: (1987)

$R(D^\ast)$ status
por: Wormser, Guy Henri Maurice
Publicado: (2017)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

Efficacy of a Selective Binder of α(V)β(3) Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models
por: Sartori, Andrea, et al.
Publicado: (2019)

Top Physics at ATLAS 003
por: Stavropoulos, G D
Publicado: (2004)

Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report
por: Guo, Xiaodan, et al.
Publicado: (2022)

B, D spectroscopy and \bar B-> D/D ^\ast /D ^\ast\astl\bar\nu
por: Bloch, D
Publicado: (1995)

Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening
por: Kuo, Yuan-Hung, et al.
Publicado: (2019)

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
por: Amin, Asim, et al.
Publicado: (2015)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_v653mr7cd32un57tq2o8r2uh9d